- Northland Capital's Suraj Kalia says there are "glaring inconsistencies" between what HeartWare International (HTWR +0.8%) says about the final protocol for a destination therapy submission and what one of the principal investigators on the trial says.
- Northland says Dr. Joseph Rogers expects to present data from the trial next year, but the company seems to say otherwise.
- Rogers and the company also seem to disagree about whether or not data should be aggregated.
- "How do you expect PI's to successfully 'defend' the trial, especially when they haven't been consulted about data analysis or presentation," Kalia asks.
at Zacks.com (Oct 30, 2014)